Enterprise Value
546M
Cash
200.5M
Avg Qtr Burn
-22.76M
Short % of Float
9.74%
Insider Ownership
9.77%
Institutional Own.
86.16%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
4D-150 Details Wet age-related macular degeneration | Phase 2 Data readout | |
4D-150 Details Diabetic macular edema | Phase 2 Data readout | |
4D-710 Details Cystic fibrosis | Phase 2 Initiation | |
4D-125 Details X-linked retinitis pigmentosa | Phase 1/2 Data readout | |
4D-310 Details Fabry disease | Phase 1/2 Data readout | |
4D-110 Details Choroideremia | Phase 1 Data readout |